IFNA1 and hepatocellular carcinoma: Viral eradication based on interferon (IFN) and direct-acting antiviral (DAA) agents benefits patient prognosis by reducing the incidence of extrahepatic morbidity [1], hepatocellular carcinoma (HCC) [2, 3], and liver-related events (LREs) [4].